Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Kreitman

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Current Pharmaceutical Biotechnology|January 5, 2002
Toxin-labeled monoclonal antibodiesR J Kreitman
Current Opinion in Investigational Drugs (London, England : 2000)|November 23, 2001
Chimeric fusion proteins--Pseudomonas exotoxin-basedR J Kreitman
Current Opinion in Immunology|October 6, 1999
Immunotoxins in cancer therapyR J Kreitman
Expert Opinion on Pharmacotherapy|March 16, 2001
ImmunotoxinsR J Kreitman
Expert Opinion on Investigational Drugs|July 5, 2005
IBC's international Conference on Novel Therapeutic Proteins for Oncology (drug discovery and development)R J Kreitman
Methods in Molecular Biology (Clifton, N.J.)|February 24, 2001
Quantification of immunotoxin number for complete therapeutic responseR J Kreitman
Expert Opinion on Investigational Drugs|July 5, 2005
Recombinant toxins in haematologic malignancies and solid tumoursR J Kreitman
Leukemia Research|December 24, 1997
Getting plant toxins to fuseR J Kreitman
Methods in Molecular Medicine|February 15, 2011
12 making fusion toxins to target leukemia and lymphomaR J Kreitman, I Pastan
Cancer Research|March 21, 1998
Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responsesR J Kreitman, I Pastan
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Current Pharmaceutical Biotechnology|January 5, 2002
Toxin-labeled monoclonal antibodiesR J Kreitman
Current Opinion in Investigational Drugs (London, England : 2000)|November 23, 2001
Chimeric fusion proteins--Pseudomonas exotoxin-basedR J Kreitman
Current Opinion in Immunology|October 6, 1999
Immunotoxins in cancer therapyR J Kreitman
Expert Opinion on Pharmacotherapy|March 16, 2001
ImmunotoxinsR J Kreitman
Expert Opinion on Investigational Drugs|July 5, 2005
IBC's international Conference on Novel Therapeutic Proteins for Oncology (drug discovery and development)R J Kreitman
Methods in Molecular Biology (Clifton, N.J.)|February 24, 2001
Quantification of immunotoxin number for complete therapeutic responseR J Kreitman
Expert Opinion on Investigational Drugs|July 5, 2005
Recombinant toxins in haematologic malignancies and solid tumoursR J Kreitman
Leukemia Research|December 24, 1997
Getting plant toxins to fuseR J Kreitman
Methods in Molecular Medicine|February 15, 2011
12 making fusion toxins to target leukemia and lymphomaR J Kreitman, I Pastan
Cancer Research|March 21, 1998
Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responsesR J Kreitman, I Pastan
Pageof 11